American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy
American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy
复制标题
DOI：
--
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
J. Saukkonen;D. Cohn;R. Jasmer;S. Schenker;J. Jereb;C. Nolan;C. Peloquin;F. Gordin;D. Nunes;D. Strader;J. Bernardo;R. Venkataramanan;T. Sterling
中科院分区：
文献类型：
--
作者：
J. Saukkonen;D. Cohn;R. Jasmer;S. Schenker;J. Jereb;C. Nolan;C. Peloquin;F. Gordin;D. Nunes;D. Strader;J. Bernardo;R. Venkataramanan;T. Sterling
Methods The Liver: Structure and Function Hepatic Drug Metabolism: Transporters, Enzymes, and Excretion Drug-induced Liver Injury: General Concepts Definition Dimensions of the Problem Pathogenesis of DILI Hepatic Enzyme Measurement Types of DILI DILI during Treatment of Latent TB Infection Isoniazid Rifampin Isoniazid and Rifampin Pyrazinamide Rifampin and Pyrazinamide Rifabutin Ethambutol Fluoroquinolones Hepatotoxicity during Treatment of TB Disease Age over 35 Children Sex Cofactors Abnormal Baseline Transaminases Acetylator Status Other Factors Regimen HIV-infected Individuals Hepatitis B Hepatitis C DILI with Second-line Anti-TB Agents Recommendations regarding TB DILI Program Infrastructure Provider Education and Resources Pretreatment Clinical Evaluation Patient Education Medication Administration and Pharmacy Treatment of LTBI Treatment of TB Disease Priorities for Research of Hepatotoxicity in Treatment of LTBI and of TB Disease Conclusions
